30 Day Trial

DePuy Synthes/JNJ Reports 4Q15 and 2015 Revenue

Share:

DePuy Synthes posted 2015 orthopaedic revenue of US $9,262MM, -4.3% as reported and +1.7% operational (excludes the effect of currency).

Operational growth: U.S. $5,380MM, +3.5%; ex-U.S. $3,882MM, -0.3%

  • Hips $1,332MM, +3.2%
  • Knees $1,496MM, +2.8%
  • Trauma $2,528MM, +2.0%
  • Spine & Other $3,906MM, +0.7%

*Other comprises Sports Medicine, Neuro, Shoulders, CMF and Power Tools

Source: DePuy Synthes, a Johnson & Johnson company

 

ORTHOWORLD estimates 2015 segment sales and growth on an as-reported basis, as follows.

  • Joint Reconstruction $3,289.9MM, -2.6%
  • Trauma $2,424.6MM, -4.4%
  • Arthroscopy/Soft Tissue Repair $654.5MM, -2.2%
  • Spine $1,325.7MM, -8.0%
  • Orthobiologics $396.2MM, -2.6%

 

JNJ recently announced plans to restructure certain portions of its business, including changes that will affect its Medical Devices segment, including DePuy Synthes. Restructuring actions are expected to yield annualized pre-tax cost savings of US $0.8BB to $1.0BB by end of 2018, including ~$200MM in 2016.